First French pharmaceutical establishment in cell therapy

Neonatal stem cells: an essential tool for future veterinary practice
Innovative high-tech biotherapies for animal health
Bringing the best of regenerative medicine to as many as possible

Our Vision

Our Vision

Improving the quality of life and performance of animals and humans through biotherapies that respect the environment and animal welfare.

Our Missions

Our Missions

Vetbiobank develops and manufactures innovative, practical and widely available veterinary biotherapies to treat chronic inflammatory or immune animal diseases related to age or trauma.

Our Expertise

Our Expertise

Industrial and multi-species manufacturing of neonatal stem cells and clinical development in compliance with Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP).
Vetbiobank has a unique industrial and clinical know-how in regenerative veterinary medicine.

Our Strategy

Our Strategy

Vetbiobank offers major players in the veterinary and human pharmaceutical industry a pipeline of innovative therapies at various stages of clinical validation, from proof of concept to marketing authorization, to ensure their availability to the largest number of prescribers and patients. 

Our Achievements and Challenges

Our Achievements and Challenges

Après avoir développé sur son site R&D de Marcy l?Etoile un process de fabrication propriétaire et totalement intégré de cellules souches mésenchymateuses néonatales, nous avons ouvert à Lyon (France) un établissement pharmaceutique certifié BPF (Bonnes Pratiques de Fabrication) pour la bioproduction industrielle de cellules thérapeutiques de grade clinique

Our flagship product targeting the canine osteoarthritis market, which is worth 1.9 billion euros. It is entering its final phase of clinical development in view of obtaining European marketing authorization from the EMA. It will then be marketed by a renowned industrial partner belonging to the top 10 in the veterinary pharmaceutical industry under an exclusive partnership.

Our pipeline includes other developments such as canine atopic dermatitis and feline gingivostomatitis which are currently being offered to other industrial partners who, in both veterinary and human medicine, are eager to find new growth areas and who see cell therapy as tomorrow's therapeutics.

Vetbiobank relies on strategic collaborations to complete the clinical validation of its products and to meet the industrial challenges of cell therapy, i.e. to produce on a large scale while reducing the cost of treatment, thus making them accessible to the greatest number.

Our Ambition

Our Ambition


As a pioneer and key player in veterinary cell therapy, Vetbiobank aims to be the leading partner of the pharmaceutical industry in veterinary and human health for the development and production of drugs for new or innovative therapies. 

Thanks to its research and development work, Vetbiobank has succeeded in developing "universal" treatments whose safety and efficacy have been scientifically proven B, C, E and are financially accessible to animal owners.

Our Commitments

Our Commitments



First French Pharmaceutical company Manufacturer Establishment in Cellular Therapy

In November 2019 Vetbiobank obtained the opening authorization No. V240633/19 from its Veterinary Pharmaceutical Establishment for the manufacture of veterinary drugs undergoing clinical trials.

In April 2021, Vetbiobank is the first French laboratory to obtain the Good Manufacturing Practices (GMP) certification for its veterinary cell therapy drugs (certificate n°21/291457).

Environmental concern

Environmental concern

Limiting the release of bioactive molecules or chemicals into the environment: logistics/storage/manufacturing to limit the use of fossil fuels (plastic; fuel; LN2)

Animal welfare

Animal welfare

Vetbiobank has made the ethical choice to work with neonatal stem cells collected from placentas at birth. We recover neonatal tissues considered as biological waste and expelled during childbirth.

Unlike fat or blood tissue samples, the collections are carried out without any invasive medical procedure when giving birth to puppies, foals, kittens, etc...

The Vetbiobank Team

The Vetbiobank Team

Stéphane Maddens

CEO & Founder

Specialized Pharmacist in Cell Therapy (University of Toulouse) and PhD in Stem Cell Biology (University of Toulouse) MBA Change & Innovation (IAE - Aix en Provence - Aix-Marseille University) - 15 years of experience in human and animal regenerative medicine

Nadia Plantier

COO Business Development

Business Development, Distribution - Master biology - Biochemistry (Catholic University of Lyon) - Executive MBA (EM Lyon Business School) - 10 years VP Bus. Dev in innovative diagnostics and more than 15 years of experience in international marketing of veterinary products

Nathalie Saulnier


Master's degree in Biotechnology (University of Lyon) - PhD in human mesenchymal stromal cells (Catholic University of Roma) - Since 2012 at Vetbiobank: author of 6 articles in scientific journals on animal stem cells

Harald Egelhofer

Head of Biomanufacturing and Chief Quality Officer

Pharmacist - Masters in Experimental Pharmacology and Biostatistics - Master in Organ and TIssue Transplantation (Dijon Medical School) - 25 years of experience in human advanced therapy drugs and the implementation of Good Manufacturing Practices for cellular therapies

Marine Febre

Head of Clinical Studies

BSc in animal sciences - professional MSc in preclinical and clinical studies - certificate in animal experimentation level 1 (certification obtained at Claude Bernard University, Lyon) - Marine holds a master's degree in integrative biology and animal experimentation

Clément Robert

Bio-manufacturing Ingineer

Master's Degree in Physiology and Neurosciences (University Claude Bernard Lyon 1) - Clément holds a Master's Degree in Physiology and Neurosciences

Tiffany Thevenard

Technician - Biomanufacturing

BSc in Tissue Culture and Molecular Biology (Université IUT Dijon) - Tiffany holds a BSc in Tissue Culture and Biology molecular

Rodolphe Rakic

R&D Scientist

M.Sc. in Biology (University of Caen Normandy) - Ph.D. in Molecular and Cellular Biology (University of Caen Normandy) - Rodophe holds a Ph.D. in Molecular and Cellular Biology.

Françoise Julien

Administrative and Customer Service Manager

BSc in Business Management (University of Saint Etienne) - With more than 20 years of experience in administrative and accounting management

Violaine Tanguy

Quality Control - Technician

The History of Vetbiobank

The History of Vetbiobank

Focus on regenerative veterinary medicine
While in the United States, veterinary regenerative medicine is developing with techniques based on the use of autologous bone marrow or fat cells (at prohibitive costs, then reserved for a restricted group of owners), Stéphane Maddens anticipates the major interest that the use neonatal stem cells in animal health would represent. An entrepreneurial project was then born in his mind.

Business and managerial skills
To embark on this adventure, he decided to complete his scientific background with an MBA "Change and Innovation", delivered by the IAE of Aix en Provence. There, with the help of a group of friends, he validates the market opportunity that this breakthrough innovation represents.

Vetbiobank's inception
In 2010, he obtained the support of VetAgro-Sup, the Veterinary School of Lyon, and after having successfully developed the first neonatal equine cell bank, he founded Vetbiobanka BANK of BIOlogical VETerinary products.
He then demonstrated the safety and efficacy of these cells in competition horses, and the objective became realistic: to market the first veterinary drug based on neonatal stem cells for the treatment of canine osteoarthritis that is manufactured on an industrial scale to allow its use by the largest number of owners.

The company's growth and expansion in canine osteoarthritis
It was then time for Stéphane to raise funds from business angels and public institutions to enable him to gradually surround himself with a team of passionate scientists who managed to adapt the technology from the horse to the dog, 1 in 5 of whom in the world suffers from osteoarthritis.

The company's future prospects
Eventually, Vetbiobank will capitalize on the development of this veterinary drug to tackle human osteoarthritis, a real public health scourge that is still without a satisfactory solution today. The data acquired in dogs, one of the best models for human osteoarthritis, will enable Vetbiobank to considerably reduce the risk and duration of clinical development in humans. Vetbiobank wants to be a recognized player among the first to bring to market a safe and effective treatment for human osteoarthritis based on neonatal stem cells that is acceptable to most public healthcare systems worldwide.

Product Pipeline

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Pivotal study Approval Marketing Launch


Canine osteoarthritis

Atopic dermatitis

Atopic dermatitis

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Pivotal study Approval Marketing Launch



Chronic kidney

Feline arthrosis

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Pivotal study Approval Marketing Launch


Equine arthrosis

Stéphane Maddens holds two PhDs, one in pharmacy and the other in stem cell biology. Literally passionate about the immunology of stem cell transplantation, Stéphane built his career successively in Toulouse Hospitals, then in the American biotech company Vertex Pharmaceuticals (Oxford, UK), before taking the head of the cell, tissue and gene therapy laboratory at the Etablissement Français du Sang where he actively develops a know-how and a detailed knowledge of the value chain from donor to patient. He also participates in various international cell and gene therapy clinical trials and manages the supply of stem cell transplants, corneas and amniotic membranes for clinical hospitals in France and abroad.
Prior to Vetbiobank, he contributed to the creation and implementation of a network of public placental blood banks (neonatal stem cells) as well as to the establishment of international accreditations (FACT Netcord / JACIE ...).

With an initial dual background in biology / sales and marketing, followed by training in corporate strategy and finance, Nadia has gained extensive experience in marketing and sales (EMEA zone) in major animal health companies (Merial / Boehringer Ingelheim and Synbiotics) and then as Vice President in charge of Business Development and Operational Management at the ImmunID start-up specialized in immunological biomarkers. Nadia coordinates Vetbiobank's operations and contributes to the establishment of partnerships, particularly with the veterinary and human pharmaceutical industry, which are key for the company.

Nathalie holds a Ph.D. in Cell Biology, with over 25 peer-reviewed scientific publications, she brings extensive expertise in product research and development and quality control. Her remarkable technical skills, developed notably in Canadian and Italian public and private laboratories, cover cell culture, molecular biology, in compliance with European Pharmacopoeia, GMP for marketing authorization applications. 

Harald has spent a large part of his career at Etablissement Français du Sang (EFS), working in the field of cellular engineering and manufacturing of drugs for innovative human therapies in a GMP certified laboratory. Harald has a solid knowledge in anti-tumor or regenerative cell engineering and a strong experience in the implementation of various bio-production strategies. Close industrial collaborations such as with PDC*Line Pharma or those established with international public consortia such as eCell France, have demonstrated his ability to design processes and production tools in line with Vetbiobank's objectives. These strategies have led him to imagine new concepts, one of which has been patented with the EFS and of which he is the sole inventor. He is deeply involved in the scale-up and industrialization of cell therapy production processes. His expertise in the field of innovative therapies in human clinical practice and his operational knowledge of the regulations in force, in particular in human cell engineering (at the national and European levels), are key assets in order to meet pharmaceutical requirements as one of the prerequisites for the granting of marketing authorization.

Marine holds a master's degree in integrative biology and animal experimentation. She has acquired exceptional knowledge and experience in setting up, coordinating and piloting clinical trials in the field. 

Marine supervises all clinical and medical studies.

Clément holds a Master's degree in Physiology and Neuroscience. He worked in a leading human pharmaceutical company where he acquired expertise in cell cutting procedures. At Vetbiobank, he is in charge of the production laboratory. 

Clément designs and executes manufacturing processes in compliance with Good Manufacturing Practices.

Tiffany holds a B.Sc. in Tissue Culture and Molecular Biology and has acquired techniques for the production and control of animal cells at Vetbiobank. She has a good technical knowledge that meets the requirements of Good Manufacturing Practices.

Rodophe holds a PhD in molecular and cell biology. His missions at Vetbiobank cover scientific development, experimental development, exploitation of results and their valorization. Thanks to his skills in fundamental and applied biotechnology, innovative strategies and entrepreneurship, he oversees the company's industrial property, new product research and patent strategy.

With more than 20 years of experience in administrative and accounting management, she is a great help in the management of commercial activities (sales and procurement).
Françoise coordinates administrative and customer services.

Description to come

For Veterinarians only

Description to come

Description to come

For Veterinarians only

Ask your veterinarian for the price of a stem cell injection at his clinic.